Longitudinal analysis of atherosclerotic cardiovascular disease risk and healthcare costs in newly diagnosed type 2 diabetes in a real-world setting

To assess longitudinal risk for atherosclerotic cardiovascular disease (ASCVD) and cost of healthcare resource utilization over 9 years in patients with or without newly diagnosed type 2 diabetes (T2DM) who had no ASCVD at baseline. This retrospective, longitudinal analysis of a large, nationwide US...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2020-05, Vol.34 (5), p.107500-107500, Article 107500
Main Authors: Weng, W., Liang, Y., Brett, J., Hobbs, T., Baeres, F.M.M.
Format: Article
Language:English
Subjects:
Age
Atherosclerosis
Atherosclerotic cardiovascular disease
Cardiovascular disease
Claims
Codes
Cost
Diabetes
Health care expenditures
Health insurance
Hypertension
Longitudinal
Medical diagnosis
Patients
Pharmacy
Risk
Type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess longitudinal risk for atherosclerotic cardiovascular disease (ASCVD) and cost of healthcare resource utilization over 9 years in patients with or without newly diagnosed type 2 diabetes (T2DM) who had no ASCVD at baseline. This retrospective, longitudinal analysis of a large, nationwide US administrative claims database compared adults with newly diagnosed T2DM (n = 22,468) and a propensity score matched non-T2DM cohort (n = 22,468). Longitudinal risk of ASCVD and total annual healthcare costs were determined. Subgroup analysis was conducted for 3 age categories: 18–44, 45–64, and 65+ years. From 2006 to 2015, ASCVD was identified in a significantly greater percentage of patients in the T2DM versus non-T2DM cohort (43.2% vs 32.3%; Hazard ratio [HR] = 1.45, P 
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2019.107500